Show simple item record

dc.contributor.authorVickers, I
dc.contributor.authorFitzgerald, M
dc.contributor.authorMurchan, S
dc.contributor.authorCotter, S
dc.contributor.authorO'Flanagan, D
dc.contributor.authorCafferkey, M
dc.contributor.authorHumphreys, H
dc.date.accessioned2011-06-30T15:11:40Z
dc.date.available2011-06-30T15:11:40Z
dc.date.issued2011-05
dc.identifier.citationSerotype distribution of Streptococcus pneumoniae causing invasive disease in the Republic of Ireland. 2011, 139 (5):783-90 Epidemiol. Infect.en
dc.identifier.issn1469-4409
dc.identifier.pmid20642870
dc.identifier.doi10.1017/S0950268810001743
dc.identifier.urihttp://hdl.handle.net/10147/135011
dc.description.abstractThe 7-valent pneumococcal conjugate vaccine (PCV7) was included in the routine infant immunization schedule in Ireland in September 2008. We determined the serotype of 977 S. pneumoniae isolates causing invasive disease between 2000-2002 and 2007-2008, assessed for the presence of the recently described serotype 6C and determined the susceptibility of isolates during 2007-2008 to penicillin and cefotaxime. Serotype 14 was the most common serotype during both periods and 7·7% of isolates previously typed as serotype 6A were serotype 6C. During 2000-2002 and 2007-2008, PCV7 could potentially have prevented 85% and 74% of invasive pneumococcal disease in the target population (i.e. children aged <2 years), respectively. The level of penicillin non-susceptibility was 17% in 2007-2008. Ongoing surveillance of serotypes is required to determine the impact of PCV7 in the Irish population and to assess the potential of new vaccines with expanded valency.
dc.language.isoenen
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pubmed/20642870en
dc.subject.meshAdolescent
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshAnti-Bacterial Agents
dc.subject.meshBacterial Typing Techniques
dc.subject.meshCefotaxime
dc.subject.meshChild
dc.subject.meshChild, Preschool
dc.subject.meshHumans
dc.subject.meshInfant
dc.subject.meshInfant, Newborn
dc.subject.meshIreland
dc.subject.meshMale
dc.subject.meshMicrobial Sensitivity Tests
dc.subject.meshMiddle Aged
dc.subject.meshPenicillins
dc.subject.meshPneumococcal Infections
dc.subject.meshPneumococcal Vaccines
dc.subject.meshSerotyping
dc.subject.meshStreptococcus pneumoniae
dc.subject.meshVaccination
dc.subject.meshYoung Adult
dc.subject.meshbeta-Lactam Resistance
dc.titleSerotype distribution of Streptococcus pneumoniae causing invasive disease in the Republic of Ireland.en
dc.typeArticleen
dc.contributor.departmentEpidemiology and Molecular Biology Unit and Irish Meningococcal and Meningitis Reference Laboratory, Children's University Hospital, Dublin, Ireland. imelda.vickers@cuh.ieen
dc.identifier.journalEpidemiology and infectionen
dc.description.provinceLeinster
html.description.abstractThe 7-valent pneumococcal conjugate vaccine (PCV7) was included in the routine infant immunization schedule in Ireland in September 2008. We determined the serotype of 977 S. pneumoniae isolates causing invasive disease between 2000-2002 and 2007-2008, assessed for the presence of the recently described serotype 6C and determined the susceptibility of isolates during 2007-2008 to penicillin and cefotaxime. Serotype 14 was the most common serotype during both periods and 7·7% of isolates previously typed as serotype 6A were serotype 6C. During 2000-2002 and 2007-2008, PCV7 could potentially have prevented 85% and 74% of invasive pneumococcal disease in the target population (i.e. children aged <2 years), respectively. The level of penicillin non-susceptibility was 17% in 2007-2008. Ongoing surveillance of serotypes is required to determine the impact of PCV7 in the Irish population and to assess the potential of new vaccines with expanded valency.


This item appears in the following Collection(s)

Show simple item record